# Liquidia Settles Litigation With United Therapeutics, Removing Patent Hurdle as Shares Surge After Hours

- URL: https://stocks.freetheai.org/news/liquidia-settles-litigation-with-united-therapeutics-removing-patent-hurdle-as-996dd1
- Published: 2026-10-14T05:11:36Z
- Category: company_news; sentiment: bullish; impact: high
- Symbols: [NASDAQ:LQDA](https://stocks.freetheai.org/symbols/NASDAQ-LQDA), [NASDAQ:UTHR](https://stocks.freetheai.org/symbols/NASDAQ-UTHR)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Shares of Liquidia Corporation (NASDAQ:LQDA) jumped 42.48% to $38.20 in after-hours trading following the announcement of a global settlement with United Therapeutics Corporation (NASDAQ:UTHR) that resolves all pending litigation between the companies. The stock had previously closed regular market hours down 3.11% at $26.81.

The agreement comes after a U.S. District Court ruling found that United Therapeutics' patent claims covering inhaled treprostinil treatment for pulmonary hypertension associated with interstitial lung disease (PH-ILD) were valid and infringed. Under the settlement, Liquidia agreed not to appeal the decision and filed to remove the PH-ILD indication from the label for YUTREPIA. However, YUTREPIA will remain available without interruption for patients with pulmonary arterial hypertension.

To resolve the litigation and antitrust-related interests, Liquidia will make a series of payments including $60.3 million this month, a net $175 million within 30 business days, and $145.4 million in two equal installments in early 2027. Management stated that payments will be funded using cash on hand, which totaled $396.1 million at the end of September, alongside ongoing product revenue. Investors will watch how YUTREPIA's commercial performance progresses following preliminary third-quarter net product sales of $222.7 million.

## Key points

- Liquidia Corporation agreed to a global settlement with United Therapeutics Corporation to end all outstanding litigation between the two biopharmaceutical firms.
- Liquidia will remove the PH-ILD indication from YUTREPIA while continuing to offer the medication for patients with pulmonary arterial hypertension.
- Financial terms require Liquidia to pay a net $175 million within 30 business days, $145.4 million in 2027, and $60.3 million to resolve antitrust interests.
- Liquidia plans to fund the settlement through ongoing YUTREPIA sales and its cash balance, which stood at $396.1 million as of September 30.

## Questions and answers

### Why did Liquidia stock rise in after-hours trading?

Liquidia stock surged after the company announced a global settlement with United Therapeutics Corporation, resolving all pending litigation between the two biotechnology firms.

### What are the main terms of the Liquidia and United Therapeutics settlement?

Liquidia will remove the PH-ILD indication from YUTREPIA's label and pay United Therapeutics over $380 million across scheduled installments, funded by cash on hand and drug sales.

### Will YUTREPIA remain available for pulmonary arterial hypertension patients?

Yes, Liquidia confirmed that YUTREPIA will continue to be available to patients treated for pulmonary arterial hypertension without interruption.